海翔药业(002099.SZ)：获得地夸磷索钠化学原料药上市申请批准通知书

Core Viewpoint - Haisheng Pharmaceutical (002099.SZ) has received approval from the National Medical Products Administration for the marketing application of Diquafosol Sodium, a P2Y2 receptor agonist used in eye drop formulation for the treatment of dry eye disease [1] Group 1 - Diquafosol Sodium acts on the P2Y2 receptors located on the conjunctival epithelium and goblet cell membranes [1] - The mechanism of Diquafosol Sodium involves upregulating intracellular calcium ion concentration, which promotes the secretion of water and mucin, thereby improving symptoms of dry eye [1]